PTPRC and non-small cell lung carcinoma: For example, Zugazagoitia et al. demonstrated that CD56 and CD4 counts measured in the CD45-positive compartment by multiplex imaging can be used as markers for predicting good clinical outcomes of NSCLC patients treated with immunotherapy [94].